We served as lead healthcare regulatory counsel, as well as provided antitrust, employee benefits and tax support, for a leading provider of 340B Drug Pricing Program services in its acquisition by a prescription benefit management subsidiary (PBM) of a leading pharmacy healthcare provider.
Pharmacy Benefit Management Acquisition
You Also May Be Interested In:
Representation of Life Sciences Company Fagron Holding USA LLC
Representation of axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.